Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset
Details
Publication Year 2024-09-05,Volume 111,Issue #9,Page 2059-2069
Journal Title
American Journal of Human Genetics
Publication Type
Research article
Abstract
Co-observation of a gene variant with a pathogenic variant in another gene that explains the disease presentation has been designated as evidence against pathogenicity for commonly used variant classification guidelines. Multiple variant curation expert panels have specified, from consensus opinion, that this evidence type is not applicable for the classification of breast cancer predisposition gene variants. Statistical analysis of sequence data for 55,815 individuals diagnosed with breast cancer from the BRIDGES sequencing project was undertaken to formally assess the utility of co-observation data for germline variant classification. Our analysis included expected loss-of-function variants in 11 breast cancer predisposition genes and pathogenic missense variants in BRCA1, BRCA2, and TP53. We assessed whether co-observation of pathogenic variants in two different genes occurred more or less often than expected under the assumption of independence. Co-observation of pathogenic variants in each of BRCA1, BRCA2, and PALB2 with the remaining genes was less frequent than expected. This evidence for depletion remained after adjustment for age at diagnosis, study design (familial versus population-based), and country. Co-observation of a variant of uncertain significance in BRCA1, BRCA2, or PALB2 with a pathogenic variant in another breast cancer gene equated to supporting evidence against pathogenicity following criterion strength assignment based on the likelihood ratio and showed utility in reclassification of missense BRCA1 and BRCA2 variants identified in BRIDGES. Our approach has applicability for assessing the value of co-observation as a predictor of variant pathogenicity in other clinical contexts, including for gene-specific guidelines developed by ClinGen Variant Curation Expert Panels.
Publisher
Cell Press
Keywords
Humans; *Breast Neoplasms/genetics; *Genetic Predisposition to Disease; *Germ-Line Mutation/genetics; Female; BRCA2 Protein/genetics; BRCA1 Protein/genetics; Fanconi Anemia Complementation Group N Protein/genetics; Middle Aged; Mutation, Missense/genetics; Adult; Tumor Suppressor Protein p53/genetics; Acmg/amp; Bp5; breast cancer; co-observation; genetics; sequencing data; variant classification
Department(s)
Familial Cancer Centre
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-26 03:32:09
Last Modified: 2024-09-26 03:32:20

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙